Company intelligence / Profile preview

White Cap

Ownership: Private
Development stage: Other

Overview

Whitecap Biosciences completed Phase 2 trials of WB007, a highly potent alpha-2 adrenergic agonist for glaucoma. The company was planning additional clinical trials for both glaucoma and geographic atrophy prior to its acquisition by Bausch + Lomb. Early results suggest promise in slowing vision loss and potentially improving vision in patients with glaucoma.

Therapeutic areas: Ophthalmology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on White Cap.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on White Cap.

Explore the full profile